Pembrolizumab Exacerbates Thyroid Diseases Shown on FDG PET/CT.

A 51-year-old woman with a history of sarcomatoid hepatocellular carcinoma, status post resection, underwent FDG PET/CT. In addition to abnormal activity elsewhere, the images showed focal activity in the isthmus of the thyroid, suggestive of malignant involvement, and diffuse mild activity in the left lobe of the thyroid, suggestive of thyroiditis. After a 10-week anti-PD-1 pembrolizumab therapy, the follow-up FDG PET/CT scan demonstrated much more intense activity in both the isthmus and the left lobe of the thyroid. Pathological examination revealed papillary thyroid cancer in the isthmus and thyroiditis in the left lobe of the thyroid.

[1]  T. Pawlik,et al.  Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A population‐based analysis , 2019, Cancer.

[2]  Wei Zhang,et al.  FDG PET/CT Imaging of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus. , 2019, Clinical nuclear medicine.

[3]  Y. Jeng,et al.  Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma , 2019, Hepatology.

[4]  S. Benvenga,et al.  Thyroid disorders induced by checkpoint inhibitors , 2018, Reviews in Endocrine and Metabolic Disorders.

[5]  R. Abgral,et al.  Progression of Focal to Diffuse Thyroid Uptake Detected by 18F-FDG PET/CT: Malignant Metastatic Disease or Benign Thyroiditis? , 2018, Clinical nuclear medicine.

[6]  R. Guo,et al.  The prognosis of subsequent surgical treatment in patients with sarcomatoid carcinoma in the liver: A retrospective study. , 2018, International journal of surgery.

[7]  Kyung Jin Cho,et al.  Clinical usefulness of FDG-PET in patients with hepatocellular carcinoma undergoing surgical resection , 2017, Annals of hepato-biliary-pancreatic surgery.

[8]  A. Dietz,et al.  Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms , 2017, The Journal of clinical endocrinology and metabolism.

[9]  S. Corsello,et al.  Endocrinological side-effects of immune checkpoint inhibitors , 2016, Current opinion in oncology.

[10]  S. Hess,et al.  [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies. , 2014, PET clinics.

[11]  H. Honda,et al.  Clinical usefulness of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

[12]  Chunjing Yu,et al.  Sarcomatoid hepatocellular carcinoma diagnosed by FDG PET/CT. , 2011, Clinical Nuclear Medicine.

[13]  M. Hickeson,et al.  Interesting image. Unsuspected synchronous thyroid carcinoma revealed on a post-therapy F-18 FDG PET/CT, in a patient with follicular lymphoma. , 2010, Clinical nuclear medicine.

[14]  H. Zhuang,et al.  Unsuspected synchronous lung cancer unveiled on FDG PET after chemotherapy for non-Hodgkin lymphoma. , 2008, Clinical nuclear medicine.